1、Investor Update F.Hoffmann-La Roche Ltd 4070 Basel Switzerland Investor Relations email: Tel.+41 61 68-88880 1/12 Ad hoc announcement pursuant to Art.53 LR Basel,24 April 2025 Roche continues good momentum into 2025 with 6%(CER)sales growth in the first quarter Group sales grew by 6%1 at constant ex

2、change rates(CER;7%in CHF),driven by high demand for newer medicines and diagnostic solutions.Pharmaceuticals Division sales rose by 8%(9%in CHF)on continued strong demand for a broad range of our medicines;top growth drivers were Phesgo(breast cancer),Vabysmo(severe eye diseases),Xolair(allergies)a

3、nd Hemlibra(haemophilia A).Diagnostics Division sales remained stable with high demand across products and regions offsetting the impact of the recent healthcare pricing reforms in China.Highlights:US approval for Evrysdi tablet for spinal muscular atrophy and Susvimo for the leading cause of diabet

4、es-related blindness EU approval for Columvi combination with chemotherapy for people with relapsed or refractory diffuse large B-cell lymphoma US acceptance of supplemental Biologics License Application for Gazyva/Gazyvaro for lupus nephritis Trontinemab for Alzheimers disease and NXT007 for haemop

5、hilia A to move into phase III Exclusive collaboration and licensing agreement with Zealand Pharma to co-develop and co-commercialise amylin analogue as a stand-alone therapy as well as a fixed-dose combination with Roches lead incretin asset CT-388 for weight loss Unveiling of novel sequencing by e

6、xpansion(SBX)technology,a new class of next-generation sequencing Announcement of plans to invest USD 50 billion in pharmaceuticals and diagnostics in the US in R&D and manufacturing over the next five years Announcement of plans to establish Roche Genentech Innovation Center Boston Outlook for 2025